Gold tier: mechanically validated evidence, with its primary source.
49 evidence items · page 2 / 2
1,189 casesPatent parasitaemia at baseline was present in 1,189 children (68.3%) among 1,740 febrile children enrolled across study sites in Ghana, Nigeria, and Uganda.
Ghana · Nigeria · Ougandapaludismepublished 2008Malaria journaleurope_pmcdocument of 9 observationsDOI 10.1186/1475-2875-7-190
10.2 %The prevalence of Plasmodium infection in blood donors in Ghana was 10.20%.
GhanapaludismeHAL · Unilimdocument of 148 observations
3,000,000,000 peopleMore than three thousand million people live with the risk of malaria.
GhanapaludismeHAL · Unilimdocument of 40 observations
Adjei et al. in Ghana and Gbessi et al. in Côte d’Ivoire reported decreased efficacy of ACT in sickle cell patients correlated with a delay in P. falciparum clearance.
GhanapaludismeHAL · Unilimdocument of 59 observations
The RTS,S/ASO1E malaria vaccine is being piloted in Ghana, Kenya, and Malawi.
Ghana · Kenya · Malawipaludismepublished 2021PloS onePubMeddocument of 7 observations
33.8 %Au Ghana, la prévalence des infections submicroscopiques à Plasmodium spp. était de 33,8 % selon Amoah et al.
GhanapaludismeHAL · Unilimdocument of 64 observations
5.7 USDIn Ghana, the treatment cost for each malaria episode varies from USD 5.70 to USD 48.73, depending on disease severity.
GhanapaludismeHAL · Unilimdocument of 40 observations
1,344 cases_averted_per_1000_childrenIn a phase 2b trial in Ghana and Kenya, vaccine impact of the RTS,S malaria vaccine, measured as cumulative number of clinical malaria cases averted per 1000 children vaccinated at month 32 post-dose 1, was 1344 for group R012-20.
Ghana · Kenyapaludismepublished 2024The Journal of infectious diseasesPubMeddocument of 9 observations
336 cases_averted_per_1000_full_dose_equivalentsIn a phase 2b trial in Ghana and Kenya, vaccine impact of the RTS,S malaria vaccine, measured as cumulative number of clinical malaria cases averted per 1000 RTS,S full-dose equivalents at month 32 post-dose 1, was 336 for group R012-20.
Ghana · Kenyapaludismepublished 2024The Journal of infectious diseasesPubMeddocument of 9 observations
50,000 episodesOver 50,000 episodes of uncomplicated malaria among children aged 12–59 months were included in the study.
Ghanapaludismepublished 2024Malaria journalPubMeddocument of 4 observations
25.72 nMSulfadoxine was less potent against Plasmodium malariae than Plasmodium falciparum in Ghana, with IC50 values of 25.72 nM versus 7.86 nM.
Ghanapaludismepublished 2025Microbiology spectrumeurope_pmcdocument of 5 observations
33 %Uncomplicated malaria was reduced by 33% over the entire study period (2020–2022) among children aged 12–59 months in the implementing districts of the Upper East Region, Ghana.
Ghanapaludismeobserved 2020-2022published 2024Malaria journalPubMeddocument of 4 observations
10,591 patients10,591 patients aged 6 months–85 years met protocol requirements for analysis in an observational study on dihydroartemisinin-piperaquine for uncomplicated malaria in Burkina Faso, Ghana, Mozambique, and Tanzania between September 2013 and April 2014.
Burkina Faso · Ghana · Mozambique · Tanzaniepaludismeobserved September 2013 to April 2014published 2016Malaria journaleurope_pmcdocument of 6 observations
94 patients94 patients were lost to follow-up in an observational study on dihydroartemisinin-piperaquine for uncomplicated malaria in Burkina Faso, Ghana, Mozambique, and Tanzania between September 2013 and April 2014.
Burkina Faso · Ghana · Mozambique · Tanzaniepaludismeobserved September 2013 to April 2014published 2016Malaria journaleurope_pmcdocument of 6 observations
No significant progress was made in reducing malaria cases between 2015 and 2017.
Ghanapaludismeobserved 2015–2017HAL · Unilimdocument of 40 observations
216,000,000 casesIn 2016, there were an estimated 216 million new cases of malaria and 445,000 deaths.
Ghanapaludismeobserved 2016HAL · Unilimdocument of 40 observations
79 %In Ghana, multivariate regression analysis showed that children with the AS genotype had 79% lower risk of malaria infection compared to those with the AA genotypes.
GhanapaludismeHAL · Unilimdocument of 81 observations
71 %Malaria prevalence in Ghana decreased from 71% in 2000 to about 51% in 2012.
Ghanapaludismeobserved 2000published 2016Malaria journalPubMeddocument of 4 observations
87.3 %Plasmodium falciparum was prevalent at 87.3% among the 142 malaria-positive participants in Mpraeso, Ghana.
Ghanapaludismeobserved 2014published 2017Malaria journalPubMeddocument of 4 observations
78.9 %The overall performance in the malaria vaccine implementation programme (MVIP) in Ghana was rated 78.9%.
Ghanapaludismepublished 2024Malaria journalPubMed
20,000,000 casesThere were 20 million fewer malaria cases in 2017 than in 2010.
Ghanapaludismeobserved 2017HAL · Unilimdocument of 40 observations
3,200,000,000 people3.2 thousand million people remain at risk of malaria.
GhanapaludismeHAL · Unilimdocument of 40 observations
880 cases_averted_per_1000_full_dose_equivalentsIn a phase 2b trial in Ghana and Kenya, vaccine impact of the RTS,S malaria vaccine, measured as cumulative number of clinical malaria cases averted per 1000 RTS,S full-dose equivalents at month 32 post-dose 1, was 880 for group Fx017-20-32.
Ghana · Kenyapaludismepublished 2024The Journal of infectious diseasesPubMeddocument of 9 observations
10 %Malaria parasitemia prevalence was 10% among people living with HIV in the urban area of Accra, Ghana.
Ghanapaludismepublished 2018Acta tropicaPubMeddocument of 4 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.